Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.Blood · 2019
   Trial
2. Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024
   Review
3. Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation.Cancers · 2023
   Review
4. [Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
   Article
5. Early diagnostic value of liver stiffness measurement in hepatic sinusoidal obstruction syndrome induced by hematopoietic stem cell transplantation.World journal of clinical cases · 2022
   Review
6. [Chinese expert consensus on the diagnosis and management of sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
   Article
7. Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates.Chemical science · 2021
   Review
8. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.Blood · 2021
   Article
9. A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial.Cancer medicine · 2020
   Article
10. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020
    Review
11. Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.Bone marrow transplantation · 2019
    Review
12. Pediatric Cancer Immunotherapy: Opportunities and Challenges.Paediatric drugs · 2018
    Review
13. Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis.mAbs
    Article

Corrections and comments

• Comment on
  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.2016
• Comment on
  Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.2016

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as